ライフサイエンスコーパス: cryoglobulinemia

1 with IgG3-IgG2a complexes in BALB/c (type II cryoglobulinemia).

2 bacterial endocarditis causing his type III cryoglobulinemia.

3 portant etiologically in the pathogenesis of cryoglobulinemia.

4 ion for therapeutically challenging cases of cryoglobulinemia.

5 herapeutic options remain limited for type I cryoglobulinemia.

6 eutical formulations and in vivo in cases of cryoglobulinemia.

7 olutions of antibodies and the mechanisms of cryoglobulinemia.

8 at greater risk of developing CKD, MPGN, and cryoglobulinemia.

9 th the renal injury and systemic features of cryoglobulinemia.

10 Risks were also increased for cryoglobulinemia.

11 patitis occurring in the setting of systemic cryoglobulinemia.

12 utic strategy for preventing renal injury in cryoglobulinemia.

13 disease, IgM-mediated neuropathies and mixed cryoglobulinemia.

14 ignificant association between cirrhosis and cryoglobulinemia.

15 show clinical or physical signs of syndromic cryoglobulinemia.

16 tients had PCT, vitiligo, lichen planus, and cryoglobulinemia.

17 ry that resembles important aspects of human cryoglobulinemia.

18 itis syndrome, Sjogren's syndrome, and mixed cryoglobulinemia.

19 s (HCV) infection is associated with type II cryoglobulinemia.

20 , for an overall prevalence of 3.0% in mixed cryoglobulinemia.

21 tion does not appear to have a role in mixed cryoglobulinemia.

22 patient was also found to have type II mixed cryoglobulinemia.

23 omerulonephritis, with or without associated cryoglobulinemia.

24 pheresis for the presumed essential type III cryoglobulinemia.

25 argest cohort of patients with type II mixed cryoglobulinemia.1 Steroids and rituximab appear to be t

26 HCV is also the major cause of mixed cryoglobulinemia, a B-lymphocyte proliferative disorder.

27 al lymphopoietin transgenic mice, a model of cryoglobulinemia and associated membranoproliferative gl

28 yte proliferative disorders, including mixed cryoglobulinemia and B-cell lymphoma.

29 A woman in her 50s with cryoglobulinemia and bilateral lower extremity ulcers of

30 in (TSLP) transgenic mice that produce mixed cryoglobulinemia and develop hepatitis.

31 fficulty of identifying infectious causes of cryoglobulinemia and emphasizes that an initial, highly

32 tic manifestations of hepatitis C, including cryoglobulinemia and glomerulonephritis.

33 coinfection with HGV in patients with mixed cryoglobulinemia and HCV infection in the United States.

34 ases, and type II/III, which is called mixed cryoglobulinemia and is seen in hepatitis C virus infect

35 Patients with HCV may develop mixed cryoglobulinemia and its sequelae, ranging from cutaneou

36 s well as extrahepatic complications such as cryoglobulinemia and lymphoma.

37 inib may be a novel therapeutic approach for cryoglobulinemia and MPGN in humans.

38 Cryoglobulinemia and parvovirus B19 serologic results we

39 tion, particularly its relationship to mixed cryoglobulinemia and related clinical syndromes.

40 ransgenic (TSLPtg) mice, which develop mixed cryoglobulinemia and severe cryoglobulinemia-associated

41 ween the prevalence in patients with type II cryoglobulinemia and the other populations studied.

42 observed infrequently in patients with mixed cryoglobulinemia and were caused by nonspecific binding

43 and function: autoantibody production, mixed cryoglobulinemia, and B cell lymphomas.

44 14 patients with HCV infection and type III cryoglobulinemia, and in 5 (13.5%) of 37 patients with H

45 found in patients with HCV infection without cryoglobulinemia, and in that population, the maximum an

46 Although hypocomplementemia, cryoglobulinemia, and more prominent hypertension and mi

47 bulinemia, none of 29 patients with type III cryoglobulinemia, and none of 6 patients with EMC were p

48 kin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thyroiditis were all <.0038, the B

49 patients with HCV infection with and without cryoglobulinemia, anti-CCP was not observed in patients

50 cal benefit in systemic lupus erythematosus, cryoglobulinemia, antineutrophil cytoplasmic antibodies+

51 iate logistic regression analysis identified cryoglobulinemia as an independent prognostic factor of

52 s with type II and 29 patients with type III cryoglobulinemia associated with HCV infection, 6 patien

53 ch develop mixed cryoglobulinemia and severe cryoglobulinemia-associated membranoproliferative glomer

54 us-prone MRL-Fas(lpr) mice can induce GN and cryoglobulinemia, but the features that confer nephritog

55 patic manifestations of HCV infection: mixed cryoglobulinemia, chronic kidney or end-stage renal dise

56 scosity, peripheral neuropathy, amyloidosis, cryoglobulinemia, cold-agglutinin disease, or evidence o

57 scosity, peripheral neuropathy, amyloidosis, cryoglobulinemia, cold-agglutinin disease, or transforme

58 sisted of the IgG3 cryoglobulin only (type I cryoglobulinemia) compared with IgG3-IgG2a complexes in

59 We propose that HCV-associated cryoglobulinemia could become clinically significant onl

60 systemic vasculitis associated with type II cryoglobulinemia (cryoglobulinemic vasculitis), a prolif

61 of clinical syndromes, including "essential" cryoglobulinemia (elicited by the hepatitis viruses) and

62 V infection, 6 patients with essential mixed cryoglobulinemia (EMC; all with type II), 50 hospital co

63 patic manifestations include sicca syndrome, cryoglobulinemia, glomerulonephritis, and porphyria cuta

64 role for hepatitis G virus (HGV) in type II cryoglobulinemia has not been defined, although prevalen

65 as high as 43% of HGV infections in type II cryoglobulinemia have also been reported.

66 sk of MPGN (HR, 2.23; 95% CI, 1.84-2.71) and cryoglobulinemia (HR, 16.91; 95% CI, 12.00-23.81) respec

67 ulins, and HCV, but not HGV, correlated with cryoglobulinemia in a longitudinal study.

68 oproliferative glomerulonephritis (MPGN) and cryoglobulinemia in chronic HCV patients.

69 Essential mixed cryoglobulinemia in humans is strongly associated with c

70 We characterized the role of cryoglobulinemia in the development of liver disease in

71 obulinemia, sera from 29 patients with mixed cryoglobulinemia (including 13 with rheumatic symptoms a

72 Cryoglobulinemia is a distinct entity characterized by t

73 Cryoglobulinemia is categorized into two main subgroups:

74 Essential mixed cryoglobulinemia is frequently associated with chronic h

75 itive anti-nuclear autoantibodies, and mixed cryoglobulinemia is increasingly reported in different p

76 Mixed cryoglobulinemia is the most common HCV extrahepatic man

77 f HCV with the extrahepatic complications of cryoglobulinemia is widely recognized, the relationship

78 lymphoproliferative disorders such as mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B

79 e B-cell lymphoproliferative disorders mixed cryoglobulinemia (MC) and non-Hodgkin lymphoma.

80 Hepatitis C virus (HCV) causes mixed cryoglobulinemia (MC) by driving clonal expansion of IgM

81 Mixed cryoglobulinemia (MC) is a B-cell lymphoproliferative di

82 Mixed cryoglobulinemia (MC) is the most common extrahepatic ma

83 Hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon

84 titis C virus (HCV) frequently develop mixed cryoglobulinemia (MC), a monoclonal expansion of immunog

85 in hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC), especially concerning the long-te

86 infection and PCT, lichen planus, vitiligo, cryoglobulinemia, membranoproliferative GN, and NHL.

87 Waldenstrom macroglobulinemia (n = 165), and cryoglobulinemia (n = 551) were increased with HCV infec

88 9%) of 34 patients with HCV-infected type II cryoglobulinemia, none of 29 patients with type III cryo

89 drome (P = 0.05), hypertension (P < 0.0001), cryoglobulinemia (P = 0.05), and preexisting intraocular

90 Two (6.9%) of the cryoglobulinemia patients had borderline-positive findin

91 Of the cryoglobulinemia patients, 22 (76%) had positive results

92 sociated with resolution of complications of cryoglobulinemia, reduced levels of insulin resistance,

93 m 50 patients with HCV infection but without cryoglobulinemia, sera from 29 patients with mixed cryog

94 The treatment of cryoglobulinemia should target the underlying disorder;

95 irus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS).

96 asculitis of low/medium sized vessels (mixed cryoglobulinemia syndrome or cryoglobulinemic vasculitis

97 The majority of patients had cryoglobulinemia that became negative after HEV clearanc

98 We report a case of recalcitrant type I cryoglobulinemia treated successfully with long-term pla

99 ransgenic animals developed polyclonal mixed cryoglobulinemia (type III) and a systemic inflammatory

100 There was no apparent difference between cryoglobulinemia types I and II regarding the role of co

101 hepatitis C virus (HCV) infection, and overt cryoglobulinemia vasculitis (CryoVas) develops in approx

102 herapeutic management of noninfectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepa

103 e in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (HCV-CV).

104 Cryoglobulinemia was induced by i.p. injection of 6-19 h

105 hospital, a diagnosis of essential type III cryoglobulinemia was made.

106 irty-six HCV patients with and without mixed cryoglobulinemia were compared with 18 healthy control v

107 Hypocomplementemia and cryoglobulinemia were present in 46 and 33% of patients,

108 le mouse model of renal involvement in mixed cryoglobulinemia, which enables detailed studies of a me

109 ia is widely recognized, the relationship of cryoglobulinemia with liver disease is unclear.

110 on for end-stage chronic hepatitis C in whom cryoglobulinemia with vasculitis developed after transpl